At the news
? BEARISHIMPACT 6/10 424B5 filed Aug 6, 2026 at 08:00 ET
CG Oncology upsized its at-the-market (ATM) equity offering by $500M to a total of $1.05B, after already selling $550M in gross proceeds via 10.8M shares. The additional capacity represents potential dilution of up to ~7.8% of shares outstanding at current prices, with proceeds earmarked for general corporate purposes including R&D and commercialization of its lead candidate, cretostimogene. The massive capital raise signals aggressive funding needs and will likely pressure the stock as the market absorbs the supply over time.
- ATM offering capacity increased by $500M to a total of $1.05B (Amendment No. 2 to Prospectus).
- Already sold 10,800,525 shares for gross proceeds of $550M under the existing ATM agreement.
- At the August 5, 2026 closing price of $72.42, the additional $500M capacity represents up to ~6.9M shares, or ~7.8% of the 88.0M shares outstanding as of March 31, 2026.
- Proceeds intended for general corporate purposes, including R&D and commercialization of cretostimogene.
Before · The news · First close · A day later · A week later
Replay the market's reaction
Step through every 5 minutes around the news, then see how it compares with similar events.
Subscribe for Full Access